A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunologic Non-Inferiority of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United Kingdom.
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Hib-DTaP-poliovirus vaccine; Hib-meningococcal vaccine group C conjugate; Meningococcal vaccine group C conjugate; Pneumococcal 7-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Wyeth
- 21 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Aug 2010 Status changed from completed to recruiting, according to UKCRN record.
- 26 Mar 2010 Follow-on study identified and integrated (NCT01095471).